Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Hematology and Oncology Specialists
mi
from
Metairie, LA
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Hematology and Oncology Specialists
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Greater Baltimore Medical Center
mi
from
Baltimore, MD
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated:  7/7/2015
The Finsen Center, Rigshospitalet
mi
from
Copenhagen,
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours
Status: Enrolling
Updated: 7/7/2015
The Finsen Center, Rigshospitalet
mi
from
Copenhagen,
Click here to add this to my saved trials
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
Status: Enrolling
Updated:  7/27/2015
START
mi
from
San Antonio, TX
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
Status: Enrolling
Updated: 7/27/2015
START
mi
from
San Antonio, TX
Click here to add this to my saved trials
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.
Status: Enrolling
Updated:  7/28/2015
Women and Infants Hospital
mi
from
Providence, RI
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.
Status: Enrolling
Updated: 7/28/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Status: Enrolling
Updated:  8/3/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Status: Enrolling
Updated: 8/3/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated:  8/26/2015
Clinical Research Facility
mi
from
La Jolla, CA
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated: 8/26/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated:  8/26/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated: 8/26/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated:  8/26/2015
Clinical Research Facility
mi
from
Augusta, GA
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated: 8/26/2015
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated:  8/26/2015
Clinical Research Facility
mi
from
Scarborough, ME
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated: 8/26/2015
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated:  8/26/2015
mi
from
Bruxelles - Brussel,
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Status: Enrolling
Updated: 8/26/2015
mi
from
Bruxelles - Brussel,
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Sharp Healthcare
mi
from
San Diego, CA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Sharp Healthcare
mi
from
San Diego, CA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
St. Vincent Gynecologic Oncology
mi
from
Indianapolis, IN
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
St. Vincent Gynecologic Oncology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Hematology and Oncology Specialists, LLC
mi
from
Covington, LA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Hematology and Oncology Specialists, LLC
mi
from
Covington, LA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Jayne Gurtler, M.D.
mi
from
Metairie, LA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Jayne Gurtler, M.D.
mi
from
Metairie, LA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Hematology and Oncology Specialists, LLC
mi
from
Metarie, LA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Hematology and Oncology Specialists, LLC
mi
from
Metarie, LA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Johns Hopkins University
mi
from
Baltimore, MD
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
The Center for Cancer and Hematologic Disease
mi
from
Cherry Hill, NJ
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
The Center for Cancer and Hematologic Disease
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Cooper University Hospital
mi
from
Voorhees, NJ
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Cooper University Hospital
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
New York Oncology Hematology PC
mi
from
Albany, NY
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Gabrail Cancer Center
mi
from
Canton, OH
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Lehigh Valley Women's Cancer Center
mi
from
Allentown, PA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Lehigh Valley Women's Cancer Center
mi
from
Allentown, PA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Gynecology Oncology Research & Development
mi
from
Greenville, SC
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Gynecology Oncology Research & Development
mi
from
Greenville, SC
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Tyler Cancer Center
mi
from
Tyler, TX
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Northern Virginia Pelvic Surgery Associates
mi
from
Annandale, VA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Northern Virginia Pelvic Surgery Associates
mi
from
Annandale, VA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Peninsula Cancer Center
mi
from
Newport News, VA
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Peninsula Cancer Center
mi
from
Newport News, VA
Click here to add this to my saved trials
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  9/4/2015
Krankenhaus Nordwest
mi
from
Frankfurt,
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 9/4/2015
Krankenhaus Nordwest
mi
from
Frankfurt,
Click here to add this to my saved trials
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated:  9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer
A Pilot Program to Personalize Care by Integrating Traditional and Complementary Medicine for Women With Ovarian Cancer
Status: Enrolling
Updated:  9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer
A Pilot Program to Personalize Care by Integrating Traditional and Complementary Medicine for Women With Ovarian Cancer
Status: Enrolling
Updated: 9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors
Status: Enrolling
Updated:  9/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors
Status: Enrolling
Updated: 9/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Hollywood, FL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Orlando, FL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Chicago, IL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Marrero, LA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Marrero, LA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Metairie, LA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Baltimore, MD
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Boston, MA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Rochester, MN
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Oklahoma City, OK
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Houston, TX
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Seattle, WA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
London,
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
London,
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials